• Citer

Real-world adherence to topical therapies in patients with moderate acne

par Lam-Hoai, Xuan-Lan ;De Maertelaer, Viviane ;Simonart, Thierry
Référence JAAD International, 2, page (109-115)
Publication Publié, 2021-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Background: Real-life data on topical treatments in daily practice in patients with moderate acne are poorly characterized. Objective: To investigate the drug survival of topical treatments administered to patients with moderate acne in a daily practice. Methods: Survival analysis was performed on subjects (Belgian university hospital and private practice outpatient dermatology patients) with moderate acne who received topical therapies according to the current published guidelines. Results: A total of 1160 treatment series (1029 patients) were included, including benzoyl peroxide (BPO, n = 93), azelaic acid (n = 246), adapalene (n = 254), a fixed combination of adapalene 0.1% and BPO 2.5% (A/BPO, n = 264), and a fixed combination of clindamycin 1.2% and tretinoin 0.025% gel (Clin-RA, n = 303). The calculated overall median treatment duration of all drugs was 2 months. The probability of treatment discontinuation after only 3 months was 50%. Overall, the drugs were discontinued for the following reasons: controlled acne (9%), side effects (9%), ineffectiveness (52%), combination of side effects and ineffectiveness (3%), and other reasons (1%). Overall, 27% patients were lost to follow-up. Limitations: The post hoc study design and generalizability limit interpretation of the data. Conclusion: Overall, the median treatment duration of topical anti-acne therapies was short (2 months). The main reason for discontinuation was ineffectiveness.